RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Intra-Cellular Therapies - Stock

Intra-Cellular Therapies Net Income 2024

Intra-Cellular Therapies Net Income

-58 M USD

Ticker

ITCI

ISIN

US46116X1019

WKN

A1XDTL

In 2024, Intra-Cellular Therapies's profit amounted to -58 M USD, a -58.47% increase from the -139.67 M USD profit recorded in the previous year.

The Intra-Cellular Therapies Net Income history

YEARNET INCOME (undefined USD)
2029e1.49
2028e1.16
2027e0.76
2026e0.41
2025e0.11
2024e-0.06
2023-0.14
2022-0.26
2021-0.28
2020-0.23
2019-0.15
2018-0.16
2017-0.1
2016-0.12
2015-0.1
2014-0.03
2013-0.03
2012-0.02
20110

Intra-Cellular Therapies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Intra-Cellular Therapies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Intra-Cellular Therapies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Intra-Cellular Therapies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Intra-Cellular Therapies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Intra-Cellular Therapies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Intra-Cellular Therapies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Intra-Cellular Therapies’s growth potential.

Intra-Cellular Therapies Revenue, Profit, and EBIT History

DateIntra-Cellular Therapies RevenueIntra-Cellular Therapies EBITIntra-Cellular Therapies Net Income
2029e3.06 B undefined0 undefined1.49 B undefined
2028e2.51 B undefined1.66 B undefined1.16 B undefined
2027e1.81 B undefined897.64 M undefined760.88 M undefined
2026e1.36 B undefined463.12 M undefined413.2 M undefined
2025e940.64 M undefined116.84 M undefined113.45 M undefined
2024e675.98 M undefined-80.78 M undefined-58 M undefined
2023464.37 M undefined-159.38 M undefined-139.67 M undefined
2022250.3 M undefined-263.6 M undefined-256.3 M undefined
202183.8 M undefined-285.7 M undefined-284.1 M undefined
202022.8 M undefined-231.2 M undefined-227 M undefined
2019100,000 undefined-154 M undefined-147.7 M undefined
20180 undefined-162.3 M undefined-155.1 M undefined
2017200,000 undefined-102.8 M undefined-97.8 M undefined
2016300,000 undefined-118.3 M undefined-116.4 M undefined
2015100,000 undefined-105.8 M undefined-104.8 M undefined
2014600,000 undefined-31 M undefined-30.7 M undefined
20132.7 M undefined-26.3 M undefined-26.9 M undefined
20123.1 M undefined-16.4 M undefined-16.6 M undefined
201123.4 M undefined11.1 M undefined4.3 M undefined

Intra-Cellular Therapies stock margins

The Intra-Cellular Therapies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Intra-Cellular Therapies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Intra-Cellular Therapies.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Intra-Cellular Therapies's sales revenue. A higher gross margin percentage indicates that the Intra-Cellular Therapies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Intra-Cellular Therapies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Intra-Cellular Therapies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Intra-Cellular Therapies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Intra-Cellular Therapies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Intra-Cellular Therapies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Intra-Cellular Therapies Margin History

Intra-Cellular Therapies Gross marginIntra-Cellular Therapies Profit marginIntra-Cellular Therapies EBIT marginIntra-Cellular Therapies Profit margin
2029e92.73 %0 %48.75 %
2028e92.73 %66.43 %46.5 %
2027e92.73 %49.57 %42.01 %
2026e92.73 %34.13 %30.45 %
2025e92.73 %12.42 %12.06 %
2024e92.73 %-11.95 %-8.58 %
202392.73 %-34.32 %-30.08 %
202291.85 %-105.31 %-102.4 %
202190.45 %-340.93 %-339.02 %
202091.67 %-1,014.04 %-995.61 %
201992.73 %-154,000 %-147,700 %
201892.73 %0 %0 %
201792.73 %-51,400 %-48,900 %
201692.73 %-39,433.33 %-38,800 %
201592.73 %-105,800 %-104,800 %
201492.73 %-5,166.67 %-5,116.67 %
201392.73 %-974.07 %-996.3 %
201292.73 %-529.03 %-535.48 %
201192.73 %47.44 %18.38 %

Intra-Cellular Therapies Aktienanalyse

What does Intra-Cellular Therapies do?

Intra-Cellular Therapies Inc is a biopharmaceutical company that focuses on developing innovative therapies for mental disorders and other severe diseases. The company was founded in 2002 in New York City and is now headquartered in Montvale, New Jersey. Intra-Cellular Therapies' business model is based on identifying and researching novel compounds that target the restoration of balance of certain neurotransmitters in the brain. The company has a wide range of technologies and development programs to validate and optimize its therapy approaches. Intra-Cellular Therapies operates in two main business areas: neurology and oncology. However, the company's focus is on developing compounds for mental disorders such as schizophrenia, bipolar disorder, or depression. One of the company's main compounds is Lumateperone, a new medication for the treatment of schizophrenia. Lumateperone has shown promising results in clinical studies and has the potential to provide significant improvement for patients with schizophrenia, particularly in terms of cognitive function and the negative symptom profile. Intra-Cellular Therapies is currently working on the approval of Lumateperone by the US Food and Drug Administration (FDA). Another important compound is ITI-007, a non-sedative atypical antipsychotic that aims to restore the balance of dopamine and serotonin in the brain. The substance has shown superior efficacy over standard medications in clinical studies and could be a new treatment option for patients with bipolar disorder and schizophrenia. Intra-Cellular Therapies plans to launch ITI-007 in the coming years. In addition to neurology, Intra-Cellular Therapies is also developing compounds for oncology. The company's main compound in this area is ITI-333, a novel inhibitor of the protein Factor VIIa, which could be used as a potential cancer therapy. ITI-333 is currently in preclinical development. In the past years, Intra-Cellular Therapies has made significant progress in developing new compounds and now has a promising product pipeline. The company has also formed partnerships with other pharmaceutical companies such as Bristol-Myers Squibb and Takeda Pharmaceuticals to further strengthen its technologies and development programs. Overall, Intra-Cellular Therapies Inc has established itself as one of the leading innovators in the field of neuropsychiatry and could play a significant role in the development of new therapeutics for mental disorders and other severe diseases in the coming years. Intra-Cellular Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Intra-Cellular Therapies's Profit Margins

The profit margins of Intra-Cellular Therapies represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Intra-Cellular Therapies's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Intra-Cellular Therapies's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Intra-Cellular Therapies's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Intra-Cellular Therapies’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Intra-Cellular Therapies Stock

How much profit has Intra-Cellular Therapies made this year?

Intra-Cellular Therapies has made -58 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -58.47% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Intra-Cellular Therapies publish its earnings?

Intra-Cellular Therapies publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Intra-Cellular Therapies?

The profits of Intra-Cellular Therapies are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Intra-Cellular Therapies?

You can learn more about the earnings of Intra-Cellular Therapies by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Intra-Cellular Therapies pay?

Over the past 12 months, Intra-Cellular Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intra-Cellular Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Intra-Cellular Therapies?

The current dividend yield of Intra-Cellular Therapies is .

When does Intra-Cellular Therapies pay dividends?

Intra-Cellular Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intra-Cellular Therapies?

Intra-Cellular Therapies paid dividends every year for the past 0 years.

What is the dividend of Intra-Cellular Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intra-Cellular Therapies located?

Intra-Cellular Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intra-Cellular Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intra-Cellular Therapies from 6/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Intra-Cellular Therapies pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Intra-Cellular Therapies in the year 2023?

In the year 2023, Intra-Cellular Therapies distributed 0 USD as dividends.

In which currency does Intra-Cellular Therapies pay out the dividend?

The dividends of Intra-Cellular Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Intra-Cellular Therapies stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Intra-Cellular Therapies

Our stock analysis for Intra-Cellular Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intra-Cellular Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.